Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

NCT00960115 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Tecemotide (L-BLP25)
DRUG: Single low dose cyclophosphamide
BIOLOGICAL: Placebo
OTHER: Saline

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]